KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Internal Medicine / 2026 / Volume: 6 Issue: 3

Effects of multimorbidity and polypharmacy on blood pressure target attainment in patients with hypertension

Alper Tuna Güven(BASKENT UNIVERSITY, FACULTY OF MEDICINE)0000-0002-6310-4240
Naciye Hocanın(BASKENT UNIVERSITY, FACULTY OF MEDICINE)0009-0003-4574-1945
Arif Emre Ambarkütükoğlu(BASKENT UNIVERSITY, FACULTY OF MEDICINE)0009-0003-2304-8568
Ceren Kaplan(BASKENT UNIVERSITY, FACULTY OF MEDICINE)0009-0007-1503-3277
Tuana Çaylayık(BASKENT UNIVERSITY, FACULTY OF MEDICINE)0009-0009-7151-4926
Yasemen Arzani Ardebili(BASKENT UNIVERSITY, FACULTY OF MEDICINE)0009-0000-4043-3765
Elif Özden(BASKENT UNIVERSITY, FACULTY OF MEDICINE)0009-0004-8795-6693
Sevcan Karasüleymanoğlu(BASKENT UNIVERSITY, FACULTY OF MEDICINE)0009-0006-9539-8710
Zülal Şahin(BASKENT UNIVERSITY, FACULTY OF MEDICINE)0009-0003-7167-8492
Sayfa
—
Yayın Tarihi
2024-07-29
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Lower diastolic BP with P&M does not reflect better control but reflects the effect of age on diastolic BP.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background Hypertension prevalence increases with age, as well as polypharmacy and multimorbidity (P&M), which are the use of multiple medications and the presence of multiple chronic diseases, respectively.
📊
Temel Bulgular & Veri:OBP 0.05), diastolic BP was lower in patients with both (all p 0.05).
💡
Sonuç & Katkı:Lower diastolic BP with P&M does not reflect better control but reflects the effect of age on diastolic BP.
🔬Tür:Research Article
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:multimorbidity · polypharmacy · hypertension

Abstract

Background Hypertension prevalence increases with age, as well as polypharmacy and multimorbidity (P&M), which are the use of multiple medications and the presence of multiple chronic diseases, respectively. Whether P&M affects attaining blood pressure (BP) goals is not clear. Methods Hypertensive patients in the general internal medicine outpatient clinic were evaluated retrospectively. Data regarding age, gender, comorbidities, medications, office BP (OBP), home BP (HBP), and ambulatory BP (ABP) were obtained. Having two or more diseases was classified as multimorbidity, whereas using five or more drugs was classified as polypharmacy. OBP 0.05), diastolic BP was lower in patients with both (all p 0.05). Conclusion P&M does not affect the achievement of office and home BP targets. Lower diastolic BP with P&M does not reflect better control but reflects the effect of age on diastolic BP.

🔖

Bu Makaleye Atıf Yap

Güven, A. T., Hocanın, N., Ambarkütükoğlu, A. E., Kaplan, C., Çaylayık, T., Ardebili, Y. A., Özden, E., Karasüleymanoğlu, S., Şahin, Z. (2024). Effects of multimorbidity and polypharmacy on blood pressure target attainment in patients with hypertension. Turkish Journal of Internal Medicine, Volume: 6 Issue: 3. https://doi.org/10.46310/tjim.1482744

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (23)

  1. Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: Core Curriculum 2019. Am J Kidney Dis. 2019 Jul;74(1):120-31. doi: 10.1053/j.ajkd.2018.12.044.
  2. Oliveros E, Patel H, Kyung S, Fugar S, Goldberg A, Madan N, Williams KA. Hypertension in older adults: Assessment, management, and challenges. Clin Cardiol. 2020 Feb;43(2):99-107. doi: 10.1002/clc.23303.
  3. Tsai WC, Wu HY, Peng YS, Yang JY, Chen HY, Chiu YL, Hsu SP, Ko MJ, Pai MF, Tu YK, Hung KY, Chien KL. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: A systematic review and meta-analysis. JAMA Intern Med. 2017 Jun 1;177(6):792-9. doi: 10.1001/jamainternmed.2017.0197.
  4. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, MacMahon S, Turnbull F, Hillis GS, Chalmers J, Mant J, Salam A, Rahimi K, Perkovic V, Rodgers A. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016 Jan 30;387(10017):435-43. doi: 10.1016/S0140-6736(15)00805-3.
  5. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei E, Algharably EAE, Azizi M, Benetos A, Borghi C, Hitij JB, Cifkova R, Coca A, Cornelissen V, Cruickshank JK, Cunha PG, Danser AHJ, Pinho RM, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023 Dec 1;41(12):1874-2071. doi: 10.1097/HJH.0000000000003480.
  6. Dąbrowska E, Narkiewicz K. Hypertension and dyslipidemia: the two partners in endothelium-related crime. Curr Atheroscler Rep. 2023 Sep;25(9):605-12. doi: 10.1007/s11883-023-01132-z.
  7. Webb AJS, Werring DJ. New insights into cerebrovascular pathophysiology and hypertension. Stroke. 2022 Apr;53(4):1054-64. doi: 10.1161/STROKEAHA.121.035850.
  8. Hebert SA, Ibrahim HN. Hypertension management in patients with chronic kidney disease. Methodist Debakey Cardiovasc J. 2022 Sep 6;18(4):41-9. doi: 10.14797/mdcvj.1119.
  9. Przezak A, Bielka W, Pawlik A. Hypertension and type 2 diabetes-The novel treatment possibilities. Int J Mol Sci. 2022 Jun 10;23(12):6500. doi: 10.3390/ijms23126500.
  10. Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020 Feb;75(2):285-92. doi: 10.1161/HYPERTENSIONAHA.119.14240.
  11. Burnier M, Damianaki A. Hypertension as cardiovascular risk factor in chronic kidney disease. Circ Res. 2023 Apr 14;132(8):1050-63. doi: 10.1161/CIRCRESAHA.122.321762.
  12. Midão L, Giardini A, Menditto E, Kardas P, Costa E. Polypharmacy prevalence among older adults based on the survey of health, ageing and retirement in Europe. Arch Gerontol Geriatr. 2018 Sep-Oct:78:213-220. doi: 10.1016/j.archger.2018.06.018.
  13. Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med. 2021 Jun;12(3):443-452. doi: 10.1007/s41999-021-00479-3.
  14. World Health Organization. Technical Series on Safer Primary Care: Multimorbidity. 13 December 2016. Available at: https://www.who.int/publications/i/item/9789241511650.
  15. Skou ST, Mair FS, Fortin M, Guthrie B, Nunes BP, Miranda JJ, Boyd CM, Pati S, Mtenga S, Smith SM. Multimorbidity. Nat Rev Dis Primers. 2022 Jul 14;8(1):48. doi: 10.1038/s41572-022-00376-4.
  16. Davies LE, Spiers G, Kingston A, Todd A, Adamson J, Hanratty B. Adverse outcomes of polypharmacy in older people: Systematic review of reviews. J Am Med Dir Assoc. 2020 Feb;21(2):181-7. doi: 10.1016/j.jamda.2019.10.022.
  17. Gupta P, Patel P, Štrauch B, Lai FY, Akbarov A, Marešová V, White CMJ, Petrák O, Gulsin GS, Patel V, Rosa J, Cole R, Zelinka T, Holaj R, Kinnell A, Smith PR, Thompson JR, Squire I, Widimský J Jr, Samani NJ, Williams B, Tomaszewski M. Risk factors for nonadherence to antihypertensive treatment. Hypertension. 2017 Jun;69(6):1113-20. doi: 10.1161/HYPERTENSIONAHA.116.08729.
  18. Wimmer BC, Cross AJ, Jokanovic N, Wiese MD, George J, Johnell K, Diug B, Bell JS. Clinical outcomes associated with medication regimen complexity in older people: A systematic review. J Am Geriatr Soc. 2017 Apr;65(4):747-53. doi: 10.1111/jgs.14682.
  19. George J, Vuong T, Bailey MJ, Kong DCM, Marriott JL, Stewart K. Medication regimen complexity and adherence in patients at risk of medication misadventure. JPPR. 2006 Jun 1;36(2):99-102. doi:10.1002/j.2055-2335.2006.tb00580.x.
  20. Warwick J, Falaschetti E, Rockwood K, Mitnitski A, Thijs L, Beckett N, Bulpitt C, Peters R. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 2015 Apr 9;13:78. doi: 10.1186/s12916-015-0328-1.
  21. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, Kitzman DW, Kostis JB, Krousel-Wood MA, Launer LJ, Oparil S, Rodriguez CJ, Roumie CL, Shorr RI, Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright JT Jr, Pajewski NM; SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: A randomized clinical trial. JAMA. 2016 Jun 28;315(24):2673-82. doi: 10.1001/jama.2016.7050.
  22. Franklin SS, Gustin W 4th, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997 Jul 1;96(1):308-15. doi: 10.1161/01.cir.96.1.308.
  23. Cepeda M, Pham P, Shimbo D. Status of ambulatory blood pressure monitoring and home blood pressure monitoring for the diagnosis and management of hypertension in the US: an up-to-date review. Hypertens Res. 2023 Mar;46(3):620-9. doi: 10.1038/s41440-022-01137-2.